| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints |
| 22 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Disc Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) 6,000,000 shares of its common stock, par value $0.0001 per share (the “F... |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectat... |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 |
| 30 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On June 25, 2026, Disc Medicine, Inc. (the “Company”) entered into a First Amendment to Loan Agreement (the “Amendment”) to the Loan and Security Agreement dated as of November 6, 2024 (as amended, the “Loan Agreement”) among the Company... |
| 24 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, Disc Medicine, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals set forth below, eac... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 |
| 27 Feb 2026 |
8-K: Costs Associated with Exit or Disposal Activities
On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management began implementing, a restructuring plan (the “Restructuring Plan”) to better align the Company’s workforce with its near-term s... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026 |
| 17 Feb 2026 |
8-K: Regulation FD Disclosure
Disclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectat... |
| 13 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Certain identified information has been excluded from this exhibit. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA review |
| 08 Dec 2025 |
8-K: Other Events
2025 ASH Management Call December 7, 2025 Confidential Exhibit 99.1 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner’s National Priority Voucher (CNPV), which is designed to shorten the... |
| 22 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Disc Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (a) 2,619,049 shares of its common stock, par value $0.0001 per share (th... |
| 20 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Disclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectat... |
| 17 Oct 2025 |
8-K: Other Events
On October 16, 2025, Disc Medicine, Inc. (the "Company") announced that it received a Commissioner’s National Priority Voucher ("CNPV") from the U.S. Food and Drug Administration ("FDA") for bitopertin in erythropoietic protoporphyria ("... |
| 06 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 3, 2025, Mona Ashiya, Ph.D., a Class I member of the Board of Directors (the “Board”) of Disc Medicine, Inc. (the “Company”), notified the Company of her resignation from the Board, effective October 3, 2025. Dr. Ashiya was a ... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meeting |
Loading...